Paper Details

  1. Home
  2. Paper Details

FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).

Author:

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This report provides updated recommendations for the use of bivalent HPV vaccine (Cervarix) and quadrivalent HPV vaccine (Gardasil) in females aged 10-25 years and 9-26 years, respectively.
Paper Details　
Original Abstract of the Article :
On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. Cervarix is the second human papillomavirus (HPV) vaccine licensed for use in females in the United States. Quadri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20508593

データ提供：米国国立医学図書館（NLM）

HPV Vaccination: A Desert Oasis of Protection

The quest for effective preventive measures against cervical cancer, a formidable foe, has been a long and arduous journey. This report provides updated recommendations for routine and catch-up HPV vaccination of females, highlighting the licensing of the bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. The report also discusses the previous licensing of the quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co, Inc.) and the Advisory Committee on Immunization Practices (ACIP) recommendations for routine and catch-up vaccination of females.

HPV Vaccination: A Powerful Weapon Against Cervical Cancer

This report underscores the importance of HPV vaccination as a critical tool for preventing cervical cancer. The ACIP recommendations for routine and catch-up vaccination provide a clear roadmap for healthcare professionals to ensure that females are adequately protected against this devastating disease. By expanding access to HPV vaccination, we can make significant strides in reducing the incidence of cervical cancer.

Navigating the Desert of Cervical Cancer: A Journey of Prevention

The development and widespread adoption of HPV vaccines have revolutionized the fight against cervical cancer. This report serves as a vital guide for healthcare professionals, emphasizing the importance of routine HPV vaccination for all eligible females. By prioritizing prevention through vaccination, we can create a future where cervical cancer is a distant memory, like a forgotten oasis in a vast desert.

Dr.Camel's Conclusion

This report provides updated recommendations for routine and catch-up HPV vaccination of females, highlighting the importance of HPV vaccination as a critical tool for preventing cervical cancer. By expanding access to HPV vaccination, we can make significant strides in reducing the incidence of this devastating disease.

Date :
  1. Date Completed 2010-06-02
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

20508593

DOI: Digital Object Identifier

mm5920a4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.